Sangamo BioSciences is a genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Giroctocogene fitelparvovec (SB-525), its lead product candidate, which is a gene therapy for the treatment of hemophilia A that Co. is developing with its collaborator Pfizer Inc.; ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease; BIVV003, its cell therapy product candidate for the treatment of sickle cell disease that Co. is developing with its collaborator, Sanofi S.A.; and ST-400, its cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. The SGMO stock yearly return is shown above.
The yearly return on the SGMO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SGMO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|